XML 34 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended
Mar. 31, 2015
Segment
Mar. 31, 2014
Dec. 31, 2014
Summary of Significant Accounting Policies [Line Items]      
Net cash used in operating activities $ 238,793,000us-gaap_NetCashProvidedByUsedInOperatingActivities $ (22,611,000)us-gaap_NetCashProvidedByUsedInOperatingActivities  
Net cash provided by financing activities 13,812,000us-gaap_NetCashProvidedByUsedInFinancingActivities (6,531,000)us-gaap_NetCashProvidedByUsedInFinancingActivities  
Goodwill and intangible assets 1,100,000,000opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets   1,100,000,000opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets
Amortization of intangible assets 2,665,000us-gaap_AmortizationOfIntangibleAssets 2,744,000us-gaap_AmortizationOfIntangibleAssets  
Revenue from services 2,069,000us-gaap_SalesRevenueServicesNet 1,970,000us-gaap_SalesRevenueServicesNet  
Total deferred revenue related to other revenues 288,800,000us-gaap_DeferredRevenue   6,700,000us-gaap_DeferredRevenue
Allowance for doubtful accounts receivable (1,691,000)us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent   (1,906,000)us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent
Equity-based compensation expense for continuing operations 7,382,000us-gaap_ShareBasedCompensation 3,579,000us-gaap_ShareBasedCompensation  
Number of reportable segments 2us-gaap_NumberOfReportableSegments    
Pharmaceutical      
Summary of Significant Accounting Policies [Line Items]      
Number of operating segments 2us-gaap_NumberOfOperatingSegments
/ us-gaap_StatementBusinessSegmentsAxis
= opk_PharmaceuticalMember
   
Diagnostics      
Summary of Significant Accounting Policies [Line Items]      
Number of operating segments 2us-gaap_NumberOfOperatingSegments
/ us-gaap_StatementBusinessSegmentsAxis
= opk_DiagnosticsMember
   
Neovasc      
Summary of Significant Accounting Policies [Line Items]      
Revenue from services 200,000us-gaap_SalesRevenueServicesNet
/ dei_LegalEntityAxis
= opk_NeovascMember
100,000us-gaap_SalesRevenueServicesNet
/ dei_LegalEntityAxis
= opk_NeovascMember
 
Minimum      
Summary of Significant Accounting Policies [Line Items]      
Intangible assets, estimated useful lives 3 years    
Maximum      
Summary of Significant Accounting Policies [Line Items]      
Intangible assets, estimated useful lives 10 years    
Restatement Adjustment      
Summary of Significant Accounting Policies [Line Items]      
Net cash used in operating activities   (6,400,000)us-gaap_NetCashProvidedByUsedInOperatingActivities
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember
 
Net cash provided by financing activities   6,400,000us-gaap_NetCashProvidedByUsedInFinancingActivities
/ us-gaap_StatementScenarioAxis
= us-gaap_RestatementAdjustmentMember
 
Pfizer [Member]      
Summary of Significant Accounting Policies [Line Items]      
Revenue from sale of intellectual property $ 12,500,000opk_RevenueFromSaleOfIntellectualProperty
/ us-gaap_CounterpartyNameAxis
= opk_PfizerMember